Abstract:Recently, targeted degradation has emerged as a powerful therapeutic modality. Relying on "event-driven" pharmacology, proteolysis targeting chimeras (PROTACs) can degrade targets and are superior to conventional inhibitors against undruggable proteins. Unfortunately, PROTAC discovery is limited by warhead scarcity and laborious optimization campaigns. To address these shortcomings, analogous protein-based heterobifunctional degraders, known as bioPROTACs, have been developed. Compared to small-molecule PROTACs, bioPROTACs have higher success rates and are subject to fewer design constraints. However, the membrane impermeability of proteins severely restricts bioPROTAC deployment as a generalized therapeutic modality. Here, we present an engineered bioPROTAC template able to complex with cationic and ionizable lipids via electrostatic interactions for cytosolic delivery. When delivered by biocompatible lipid nanoparticles, these modified bioPROTACs can rapidly degrade intracellular proteins, exhibiting near-complete elimination (up to 95% clearance) of targets within hours of treatment. Our bioPROTAC format can degrade proteins localized to various subcellular compartments including the mitochondria, nucleus, cytosol, and membrane. Moreover, substrate specificity can be easily reprogrammed, allowing modular design and targeting of clinically-relevant proteins such as Ras, Jnk, and Erk. In summary, this work introduces an inexpensive, flexible, and scalable platform for efficient intracellular degradation of proteins that may elude chemical inhibition.

Ligation to Scavenging Strategy Enables On-Demand Termination of Targeted Protein Degradation

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Small Molecule PROTACs in Targeted Therapy: an Emerging Strategy to Induce Protein Degradation.

A modular PROTAC design for target destruction using a degradation signal based on a single amino acid

Opportunities and Challenges of Small Molecule Induced Targeted Protein Degradation

In Vivo Target Protein Degradation Induced by PROTACs Based on E3 Ligase DCAF15

Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation

Stimuli‐Responsive PROTACs for Controlled Protein Degradation

Bifunctional Peptide Nanofibrils for Targeted Protein Degradation.

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

Lipid-mediated intracellular delivery of recombinant bioPROTACs for the rapid degradation of undruggable proteins

Exploiting the Cullin E3 Ligase Adaptor Protein SKP1 for Targeted Protein Degradation

Inducible Degradation of Oncogenic Nucleolin Using an Aptamer-Based PROTAC

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

Precise Modulation of Protein Degradation by Smart PROTACs

Stimuli-activatable PROTACs for precise protein degradation and cancer therapy

Conditional PROTAC: Recent Strategies for Modulating Targeted Protein Degradation

Enzyme-catalyzed Activation of Pro-PROTAC for Cell-selective Protein Degradation

Harnessing the E3 Ligase KEAP1 for Targeted Protein Degradation

Optimization of PROTAC Ternary Complex Using DNA Encoded Library Approach

Delivering on Cell‐Selective Protein Degradation Using Chemically Tailored PROTACs